ATE512674T1 - Angiopep-1, verwandte verbindungen, und deren verwnedungen - Google Patents
Angiopep-1, verwandte verbindungen, und deren verwnedungenInfo
- Publication number
- ATE512674T1 ATE512674T1 AT04700102T AT04700102T ATE512674T1 AT E512674 T1 ATE512674 T1 AT E512674T1 AT 04700102 T AT04700102 T AT 04700102T AT 04700102 T AT04700102 T AT 04700102T AT E512674 T1 ATE512674 T1 AT E512674T1
- Authority
- AT
- Austria
- Prior art keywords
- blood
- brain barrier
- carrier
- relates
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43798603P | 2003-01-06 | 2003-01-06 | |
| PCT/CA2004/000011 WO2004060403A2 (en) | 2003-01-06 | 2004-01-05 | Aprotinin and anglos as carriers across the blood-brain barrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE512674T1 true ATE512674T1 (de) | 2011-07-15 |
Family
ID=32713262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04700102T ATE512674T1 (de) | 2003-01-06 | 2004-01-05 | Angiopep-1, verwandte verbindungen, und deren verwnedungen |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9221867B2 (de) |
| EP (2) | EP1583562B1 (de) |
| JP (2) | JP4903036B2 (de) |
| CN (2) | CN102775472A (de) |
| AT (1) | ATE512674T1 (de) |
| AU (2) | AU2004203682B2 (de) |
| BR (1) | BRPI0406647A (de) |
| CA (1) | CA2516056C (de) |
| CY (1) | CY1111844T1 (de) |
| DK (1) | DK1583562T3 (de) |
| ES (1) | ES2368941T3 (de) |
| MX (1) | MXPA05007322A (de) |
| PT (1) | PT1583562E (de) |
| SI (1) | SI1583562T1 (de) |
| WO (1) | WO2004060403A2 (de) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE512674T1 (de) | 2003-01-06 | 2011-07-15 | Angiochem Inc | Angiopep-1, verwandte verbindungen, und deren verwnedungen |
| WO2006081171A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| MX2007010113A (es) * | 2005-02-18 | 2007-12-07 | Angiochem Inc | Polipeptidos de aprotinina para transportar un compuesto a traves de la barrera hematoencefalica. |
| PL2233156T3 (pl) * | 2005-07-15 | 2013-09-30 | Angiochem Inc | Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych |
| US20110077204A1 (en) * | 2006-01-24 | 2011-03-31 | Kagoshima University | Agent for Targeted Drug Delivery To Cerebral Neurons |
| US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| JP2010506860A (ja) | 2006-10-19 | 2010-03-04 | アンジオケム，インコーポレーテッド | Ｐ−糖タンパク質機能を刺激するための化合物およびその使用 |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| JP5844971B2 (ja) * | 2007-05-29 | 2016-01-20 | アンジオケム，インコーポレーテッド | コンジュゲートされた物質を組織に送達するためのアプロチニン様ポリペプチド |
| CA2688344C (en) | 2007-05-29 | 2019-09-03 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| WO2009085200A2 (en) | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| CN102026667B (zh) | 2008-04-18 | 2014-06-25 | 安吉奥开米公司 | 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途 |
| US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
| US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
| US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
| US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
| US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| US10448989B2 (en) | 2009-04-09 | 2019-10-22 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
| US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
| US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
| US12697172B2 (en) | 2008-04-29 | 2026-08-04 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| EP2280741A4 (de) | 2008-04-29 | 2012-06-13 | Virginia Tech Intell Prop | Irreversible elektroporation zur erzeugung von gewebegerüsten |
| US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
| US8828925B2 (en) * | 2008-10-15 | 2014-09-09 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| WO2010063122A1 (en) * | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| EP2373789A4 (de) | 2008-12-17 | 2012-08-29 | Angiochem Inc | Membrantyp-1-matrixmetalloproteinase-inhibitoren und ihre verwendung |
| DE102009006228A1 (de) | 2009-01-27 | 2010-07-29 | Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh | Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen |
| US8632534B2 (en) | 2009-04-03 | 2014-01-21 | Angiodynamics, Inc. | Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD) |
| US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
| RU2011146654A (ru) | 2009-04-20 | 2013-05-27 | Ангиокем Инк. | Способы лечения рака яичников с применением конъюгированного средства |
| US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| WO2011000095A1 (en) * | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| US8809362B2 (en) * | 2009-10-30 | 2014-08-19 | Keio University | Anticancer agent sensitivity-determining marker |
| EP2588490B1 (de) * | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Kurze und d-aminosäure-haltige polypeptide für therapeutische konjugate und ihre verwendungen |
| WO2012051433A2 (en) | 2010-10-13 | 2012-04-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
| KR20140026372A (ko) | 2011-02-02 | 2014-03-05 | 이무노퓨처 아이앤씨. | 혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도 |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
| CN104781276A (zh) * | 2012-08-14 | 2015-07-15 | 安吉奥开米公司 | 肽-树枝状聚合物结合物及其用途 |
| US9888956B2 (en) | 2013-01-22 | 2018-02-13 | Angiodynamics, Inc. | Integrated pump and generator device and method of use |
| NZ711373A (en) * | 2013-03-13 | 2020-07-31 | Bioasis Technologies Inc | Fragments of p97 and uses thereof |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| EP3964507A1 (de) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und verwendungen davon |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| EP3143124B1 (de) | 2014-05-12 | 2025-01-22 | Virginia Tech Intellectual Properties, Inc. | Selektive modulation intrazellulärer effekte von zellen mittels gepulster elektrischer felder |
| US12114911B2 (en) | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
| US10258699B2 (en) | 2014-10-24 | 2019-04-16 | University Of Science And Technology Of China | Angiopep and derivatives thereof for imaging amyloids |
| CN105585614B (zh) * | 2014-10-24 | 2019-06-07 | 中国科学技术大学 | 用于淀粉样蛋白显像的血管肽及其衍生物 |
| WO2016100325A1 (en) | 2014-12-15 | 2016-06-23 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
| EP3307326B9 (de) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Verfahren zur behandlung von leptomeningealer karzinomatose |
| US11207461B2 (en) | 2015-07-30 | 2021-12-28 | Anoop U. R | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| CN106188308B (zh) * | 2016-07-12 | 2019-08-20 | 西安医学院 | 一种跨血脑屏障蛋白转运体及制备方法和应用 |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
| CA3073062A1 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| JP2021512165A (ja) | 2018-01-29 | 2021-05-13 | コグノス・セラピューティクス・インコーポレイテッド | ボルテゾミブの腫瘍内送達 |
| US12390262B2 (en) | 2018-03-13 | 2025-08-19 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
| US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US10842755B2 (en) | 2018-03-23 | 2020-11-24 | University Of South Carolina | Nanoparticles for brain targeted drug delivery |
| US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
| US12214189B2 (en) | 2019-07-24 | 2025-02-04 | Virginia Tech Intellectual Properties, Inc. | Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies |
| CA3128035A1 (en) | 2020-08-13 | 2022-02-13 | Bioasis Technologies, Inc. | Combination therapies for delivery across the blood brain barrier |
| US12485279B2 (en) | 2020-11-25 | 2025-12-02 | Virginia Tech Intellectual Properties, Inc. | Methods for modulating temporal infrastructure of pulsed electric fields |
Family Cites Families (184)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| NZ219609A (en) | 1986-03-13 | 1990-09-26 | Univ Monash | Assay methods for inhibin |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
| GB2208511A (en) | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
| US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| DE3912638A1 (de) | 1989-04-18 | 1990-10-31 | Bayer Ag | Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel |
| US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
| GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| JPH07108232B2 (ja) * | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
| US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
| US5955444A (en) | 1991-08-09 | 1999-09-21 | Massachusetts Institute Of Technology | Method of inhibiting abnormal tau hyper phosphorylation in a cell |
| US5627270A (en) | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
| US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
| GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| CA2145517A1 (en) | 1992-09-25 | 1994-04-14 | Ignace Lasters | Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia - tissue factor complex |
| EP0599303A3 (de) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide-Konjugate |
| WO1994019692A1 (en) | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
| EP0820466A2 (de) * | 1995-04-04 | 1998-01-28 | Advanced Bioconcept Inc. | Fluoreszierende peptide |
| ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| JPH11504938A (ja) | 1995-05-08 | 1999-05-11 | サイオス インク． | クニッツ型プロテアーゼ阻害因子 |
| WO1996039183A1 (en) | 1995-05-31 | 1996-12-12 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector molecules |
| US5780265A (en) | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| WO1997033996A2 (en) | 1996-03-11 | 1997-09-18 | Bayer Corporation | Human bikunin |
| AU2409397A (en) | 1996-04-24 | 1997-11-12 | Rijksuniversiteit Te Groningen | A prokaryotic protein having functional and structural homology with the uman p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein |
| AU729643B2 (en) | 1996-05-01 | 2001-02-08 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
| DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| WO1998016201A1 (en) | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| WO1998039469A1 (en) | 1997-03-04 | 1998-09-11 | Bio-Technology General Corp. | Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| GB9705903D0 (en) | 1997-03-21 | 1997-05-07 | Elliott Gillian D | VP22 Proteins and uses thereof |
| ES2210761T3 (es) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| CA2327329A1 (en) | 1998-03-12 | 1999-09-16 | Georgetown University Medical Center | Cholesterol recognition sequence |
| US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
| GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US5922754A (en) | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
| EP1154782A4 (de) | 1999-02-24 | 2002-09-25 | Uab Research Foundation | Taxan derivate zur zielgerichteten krebstherapy |
| US6138375A (en) * | 1999-03-01 | 2000-10-31 | Gala Industries, Inc. | Support ring for pellet dryer screen |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| EP1214292B1 (de) | 1999-09-24 | 2007-06-13 | Genentech, Inc. | Tyrosinderivate |
| US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| DE19953696A1 (de) | 1999-11-09 | 2001-05-10 | Alexander Cherkasky | Selektive proteolytische Synzyme (SPS) |
| DE19953966A1 (de) * | 1999-11-09 | 2001-05-10 | Leica Microsystems | Verfahren und Vorrichtung zur Dickenmessung an transparenten Schichten |
| GB2360453B (en) | 2000-01-05 | 2004-09-01 | Univ Cardiff | Treatment of skin conditions |
| US20020086384A1 (en) | 2000-03-14 | 2002-07-04 | Zurit Levine | Splice variants of oncogenes |
| CA2355334A1 (en) | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
| CA2421042C (en) | 2000-10-20 | 2011-07-05 | Abbott Laboratories | The use of tiagabine for treatment of diabetic neuropathy and migraine |
| JP2004536026A (ja) | 2000-11-28 | 2004-12-02 | トランスフォーム ファーマシューティカルズ，インコーポレーティッド． | パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤 |
| WO2002076448A1 (en) | 2001-03-23 | 2002-10-03 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
| ES2464532T3 (es) | 2001-04-19 | 2014-06-03 | The Scripps Research Institute | Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa |
| WO2003102583A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| CA2450073C (en) * | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
| US7192921B2 (en) | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
| WO2003066859A2 (en) | 2002-02-07 | 2003-08-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Amino acid sequences capable of facilitating penetration across a biological barrier |
| US7101844B2 (en) | 2002-03-29 | 2006-09-05 | Creagene, Inc. | Cytoplasmic transduction peptides and uses thereof |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| JP2005537244A (ja) | 2002-06-28 | 2005-12-08 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法 |
| US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| US7319090B2 (en) | 2002-11-27 | 2008-01-15 | University Of North Carolina At Chapel Hill | Methods of treating cerebral ischemia |
| US20040102369A1 (en) | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| ATE512674T1 (de) | 2003-01-06 | 2011-07-15 | Angiochem Inc | Angiopep-1, verwandte verbindungen, und deren verwnedungen |
| US20040162284A1 (en) | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
| CA2520655A1 (en) | 2003-04-08 | 2004-11-04 | Biotempt, B.V. | Compositions for mucosal and oral administration comprising hcg fragments |
| EP1466924B9 (de) | 2003-04-11 | 2013-06-19 | Institut Pasteur | Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper |
| AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| WO2005002515A2 (en) | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| AU2004263458B2 (en) | 2003-08-08 | 2010-06-24 | Actgen, Inc. | Polypeptides having brain-localizing activity and uses thereof |
| JP2007512001A (ja) | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | Ｅｐｏミメティックペプチドおよび融合タンパク質 |
| US20050058702A1 (en) | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
| US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
| US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
| JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| EP1799826B1 (de) | 2004-09-29 | 2009-08-12 | Children's Memorial Hospital | siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN |
| US9002652B1 (en) | 2005-01-27 | 2015-04-07 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
| MX2007010113A (es) | 2005-02-18 | 2007-12-07 | Angiochem Inc | Polipeptidos de aprotinina para transportar un compuesto a traves de la barrera hematoencefalica. |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| CA2616906A1 (en) | 2005-05-12 | 2006-11-23 | Tapestry Pharmaceuticals, Inc. | Molecular constructs suitable for targeted conjugates |
| US8877714B2 (en) | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
| PL2233156T3 (pl) | 2005-07-15 | 2013-09-30 | Angiochem Inc | Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych |
| EP1904642A4 (de) | 2005-07-19 | 2008-11-26 | Univ Illinois | Transportmittel zur überquerung der blut-hirn-schranke und zum eindringen in gehirnkrebszellen sowie verwendungsverfahren dafür |
| GB0517092D0 (en) | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
| JP2009507852A (ja) | 2005-09-08 | 2009-02-26 | エムディーアールエヌエー，インコーポレイテッド | リボ核酸の細胞への送達用医薬組成物 |
| US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
| US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| EP2202239A1 (de) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAi-Hemmung von Influenza-Virus-Neubildungen |
| US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
| US8290433B2 (en) | 2007-11-14 | 2012-10-16 | Blaze Mobile, Inc. | Method and system for securing transactions made through a mobile communication device |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| CA2644712C (en) | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| US7477504B1 (en) | 2006-03-13 | 2009-01-13 | C.P.D. Technologies, Inc. | Versatile stun glove |
| KR101263294B1 (ko) | 2006-03-30 | 2013-06-04 | 글락소 그룹 리미티드 | 아밀로이드베타 펩티드에 대한 항체 |
| WO2008100328A2 (en) | 2006-07-13 | 2008-08-21 | Burnham Institute For Medical Research | METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32 |
| DK2046826T3 (da) | 2006-07-24 | 2011-10-24 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteiner |
| JP2010503710A (ja) | 2006-09-18 | 2010-02-04 | ラプトール ファーマシューティカル インコーポレイテッド | 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置 |
| JP2010506860A (ja) | 2006-10-19 | 2010-03-04 | アンジオケム，インコーポレーテッド | Ｐ−糖タンパク質機能を刺激するための化合物およびその使用 |
| US9399675B2 (en) | 2007-02-28 | 2016-07-26 | The Board Of Regents Of The University Of Oklahoma | Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration |
| ATE539089T1 (de) | 2007-03-21 | 2012-01-15 | Raptor Pharmaceutical Inc | Cyclische rezeptor-assoziierte-proteine (rap)- peptide |
| CA2688344C (en) | 2007-05-29 | 2019-09-03 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| WO2009039188A1 (en) | 2007-09-17 | 2009-03-26 | Ludwig Institute For Cancer Research Ltd | Peptides and methods for the treatment of gliomas and other cancers |
| AU2008308679B2 (en) | 2007-10-02 | 2015-01-29 | Marina Biotech, Inc. | Lipopeptides for delivery of nucleic acids |
| WO2009070597A2 (en) | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
| EP2235175A4 (de) | 2007-12-20 | 2012-04-25 | Angiochem Inc | Polypeptid-nukleinsäure-konjugate und verwendungen davon |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| ES2951646T3 (es) | 2008-02-21 | 2023-10-24 | Burnham Institute For Medical Res | Métodos y composiciones relacionados con péptidos y proteínas con elementos C-terminales |
| CN102026667B (zh) | 2008-04-18 | 2014-06-25 | 安吉奥开米公司 | 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途 |
| US20110117627A1 (en) | 2008-07-10 | 2011-05-19 | The Board Of Trustees Of The University Of Illinois | Regulation of apoptosis by neural specific splice variants of ig20 |
| WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| US8828925B2 (en) | 2008-10-15 | 2014-09-09 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| US20110288011A1 (en) | 2008-12-05 | 2011-11-24 | Jean-Paul Castaigne | Peptide therapeutic conjugates and uses thereof |
| CA2745527A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Leptin and leptin analog conjugates and uses thereof |
| WO2010063122A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| EP2373789A4 (de) | 2008-12-17 | 2012-08-29 | Angiochem Inc | Membrantyp-1-matrixmetalloproteinase-inhibitoren und ihre verwendung |
| RU2011146654A (ru) | 2009-04-20 | 2013-05-27 | Ангиокем Инк. | Способы лечения рака яичников с применением конъюгированного средства |
| US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
| CN102753187A (zh) | 2009-06-03 | 2012-10-24 | 戴瑟纳制药公司 | 肽-dicer底物试剂及其特异性抑制基因表达的方法 |
| CN103819564A (zh) | 2009-06-11 | 2014-05-28 | 安吉奥开米公司 | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| SI2453923T1 (sl) | 2009-07-14 | 2016-04-29 | Mayo Foundation For Medical Education And Research | S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere |
| WO2011041897A1 (en) | 2009-10-06 | 2011-04-14 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| EP2333074A1 (de) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substanzen und Verfahren zur Behandlung von lyosomalen Speicherkrankheiten |
| EP3338770B1 (de) | 2010-03-08 | 2023-06-07 | Sloan-Kettering Institute For Cancer Research | Cdc7-kinasehemmer und verwendungen davon |
| WO2011119549A1 (en) | 2010-03-22 | 2011-09-29 | President And Fellows Of Harvard College | Trioxacarcins and uses thereof |
| WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
| EP2558503B1 (de) | 2010-04-14 | 2015-12-09 | National Research Council of Canada | Zusammensetzungen und verfahren zur freisetzung schmerzstillender peptide im hirn |
| WO2011153642A1 (en) | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
| EP2588490B1 (de) | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Kurze und d-aminosäure-haltige polypeptide für therapeutische konjugate und ihre verwendungen |
| US8218280B2 (en) | 2010-07-08 | 2012-07-10 | Schneider Electric USA, Inc. | Secondary thermal sensor for primary conductors |
| AU2011286407A1 (en) | 2010-08-06 | 2013-02-21 | Amgen | Use of HER3 binding agents in prostate treatment |
| CN102406949B (zh) | 2010-09-21 | 2013-05-29 | 复旦大学 | 一种靶向示踪的多模式诊断纳米影像药物 |
| WO2012037687A1 (en) | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP2014505666A (ja) | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | 癌治療のための降圧剤の組成物および使用 |
| CN102552928A (zh) | 2010-12-19 | 2012-07-11 | 复旦大学 | 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法 |
| EP3238722B1 (de) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Festen formen von isochinolinonen |
| CN102614105A (zh) | 2011-01-28 | 2012-08-01 | 复旦大学 | 一种脑靶向载两性霉素b聚合物胶束给药系统 |
| US20130337051A1 (en) | 2011-03-01 | 2013-12-19 | To-Bbb Holding B.V. | Advanced active liposomal loading of poorly water-soluble substances |
| CA2831392C (en) | 2011-03-28 | 2020-04-28 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| WO2012138694A2 (en) | 2011-04-07 | 2012-10-11 | Emory University | Compositions comprising saccharide binding moieties and methods for targeted therapy |
| CA2835637A1 (en) | 2011-05-09 | 2012-11-15 | Institut Quimic De Sarria Cets Fundacio Privada | Polymeric nanoparticles for drug delivery |
| WO2013004716A1 (en) | 2011-07-04 | 2013-01-10 | Universität Basel | Peptide beads |
| EP2734520B1 (de) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und ihre verwendung |
| US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20150065524A1 (en) | 2011-08-11 | 2015-03-05 | Intellikine Llc | Kinase inhibitor polymorphs |
| PE20141371A1 (es) | 2011-08-29 | 2014-10-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| HK1201271A1 (en) | 2011-11-11 | 2015-08-28 | Intellikine, Llc | Kinase inhibitor polymorphs |
| CN104145015A (zh) | 2011-12-01 | 2014-11-12 | 安吉奥开米公司 | 靶向的溶酶体酶化合物 |
| US20140335163A1 (en) | 2011-12-01 | 2014-11-13 | Angiochem Inc. | Targeted iduronate-2-sulfatase compounds |
| CN109125286A (zh) | 2011-12-13 | 2019-01-04 | 安吉尼科分子传输公司 | 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞 |
| CA2859205A1 (en) | 2011-12-16 | 2013-06-20 | Massachusetts Institute Of Technology | Alpha-aminoamidine polymers and uses thereof |
| WO2013120107A1 (en) | 2012-02-09 | 2013-08-15 | University Of Rochester | Methods and compositions for treating a subject to inhibit hearing loss |
| EP2819686A4 (de) | 2012-03-02 | 2016-05-25 | Icahn School Med Mount Sinai | Varianten von prothymosin alpha und verfahren zur verwendung davon |
| EP2833905B1 (de) | 2012-04-04 | 2018-05-02 | Halozyme, Inc. | Kombinationbehnadlung von hyaluronidase und einem tumor-gerichteten taxane |
| WO2013162757A1 (en) | 2012-04-26 | 2013-10-31 | Yale University | Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use |
| WO2013185235A1 (en) | 2012-06-15 | 2013-12-19 | Angiochem Inc. | Targeted iduronidase compounds |
-
2004
- 2004-01-05 AT AT04700102T patent/ATE512674T1/de active
- 2004-01-05 WO PCT/CA2004/000011 patent/WO2004060403A2/en not_active Ceased
- 2004-01-05 US US10/541,304 patent/US9221867B2/en active Active
- 2004-01-05 EP EP04700102A patent/EP1583562B1/de not_active Expired - Lifetime
- 2004-01-05 PT PT04700102T patent/PT1583562E/pt unknown
- 2004-01-05 CN CN2012102486937A patent/CN102775472A/zh active Pending
- 2004-01-05 BR BR0406647-2A patent/BRPI0406647A/pt not_active Application Discontinuation
- 2004-01-05 DK DK04700102.9T patent/DK1583562T3/da active
- 2004-01-05 SI SI200431732T patent/SI1583562T1/sl unknown
- 2004-01-05 MX MXPA05007322A patent/MXPA05007322A/es active IP Right Grant
- 2004-01-05 CN CN2004800035448A patent/CN1747747B/zh not_active Expired - Fee Related
- 2004-01-05 CA CA2516056A patent/CA2516056C/en not_active Expired - Lifetime
- 2004-01-05 AU AU2004203682A patent/AU2004203682B2/en not_active Ceased
- 2004-01-05 JP JP2006500425A patent/JP4903036B2/ja not_active Expired - Fee Related
- 2004-01-05 ES ES04700102T patent/ES2368941T3/es not_active Expired - Lifetime
- 2004-01-05 EP EP10009847A patent/EP2260874A1/de not_active Withdrawn
-
2009
- 2009-12-29 AU AU2009251223A patent/AU2009251223B2/en not_active Ceased
-
2011
- 2011-09-15 CY CY20111100889T patent/CY1111844T1/el unknown
- 2011-10-28 JP JP2011237203A patent/JP2012031197A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9221867B2 (en) | 2015-12-29 |
| SI1583562T1 (sl) | 2011-10-28 |
| CN1747747B (zh) | 2012-09-05 |
| EP2260874A1 (de) | 2010-12-15 |
| JP2012031197A (ja) | 2012-02-16 |
| PT1583562E (pt) | 2011-09-19 |
| ES2368941T3 (es) | 2011-11-23 |
| US20060182684A1 (en) | 2006-08-17 |
| AU2009251223A1 (en) | 2010-01-28 |
| JP2006515363A (ja) | 2006-05-25 |
| MXPA05007322A (es) | 2006-02-17 |
| CN102775472A (zh) | 2012-11-14 |
| CN1747747A (zh) | 2006-03-15 |
| JP4903036B2 (ja) | 2012-03-21 |
| AU2009251223B2 (en) | 2012-02-09 |
| BRPI0406647A (pt) | 2005-12-06 |
| WO2004060403A3 (en) | 2004-11-18 |
| CY1111844T1 (el) | 2015-10-07 |
| EP1583562B1 (de) | 2011-06-15 |
| AU2004203682A1 (en) | 2004-07-22 |
| DK1583562T3 (da) | 2011-09-19 |
| AU2004203682A8 (en) | 2009-09-17 |
| CA2516056A1 (en) | 2004-07-22 |
| EP1583562A2 (de) | 2005-10-12 |
| WO2004060403A2 (en) | 2004-07-22 |
| CA2516056C (en) | 2012-05-29 |
| AU2004203682B2 (en) | 2009-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1583562T3 (da) | Angiopep-1, beslægtede forbindelser og anvendelser deraf | |
| NO20081005L (no) | 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | |
| TW200728276A (en) | Oxindole derivatives | |
| PT1506203E (pt) | Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações | |
| ATE536163T1 (de) | Verpackung für medizinische produkte und dergleichen | |
| FI20050932A7 (fi) | Heterobifunktionaaliset polymeeriset biokonjugaatit | |
| EP1614676A4 (de) | Verbindung zum inhibieren des in vivo-phosphortransports und arzneimittel, das dieses enthält | |
| BR0308613A (pt) | Combinação de compostos orgânicos | |
| ATE474591T1 (de) | Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung | |
| ATE438626T1 (de) | 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivate und deren salze | |
| DE602005025883D1 (de) | Träger für die enterale verabreichung | |
| ATE516284T1 (de) | Aromatische verbindungen als entzündungshemmende, immunomodulatorische und antiproliferative mittel | |
| EP2077111A4 (de) | Antidepressivum | |
| NO20091495L (no) | Pyrazolopyrimidinderivat | |
| DE602004031954D1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE516031T1 (de) | Verbindungen gegen krebs | |
| ECSP045405A (es) | Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa | |
| ATE398122T1 (de) | Dimere verbindungen und deren verwendung als antivirale mittel | |
| ATE444968T1 (de) | Neuroprotektive verbindungen und deren verwendungen | |
| AR048957A1 (es) | Derivados ciclopeptidos dotados de actividad anti-integrina. | |
| DE602004002975D1 (de) | Porphyrin-Verbindung, deren Albumin-Einschlussverbindung und künstlicher Sauerstoffträger | |
| TR200401012T4 (tr) | Mide tedavisinde kullanılan aktif olmayan ilaçlar. | |
| EP1433480A4 (de) | Pyrimidinderivate enthaltendes medikament | |
| MXPA04006600A (es) | Dihidrotiazina-y dihidrotiopiran-oxazolidinonas antimicrobianas. | |
| TH78678A (th) | ตัวยับยั้ง c-แอริลกลูโคไซด์ sglt2 และวิธี |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1583562 Country of ref document: EP |